TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3094439
Drug: Ciprofloxacin 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 0.25 g single dose
Study: 3094439
Drug: Ampicillin 3.5
Normalized name: AMPICILLIN 3.5/PROBENECID 1GM SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 3.5 g plus probenecid 1.0 g
Study: 31223624
Drug: General public
Approvals — FDA: no, EMA: no, PMDA: no
Description: General public awareness of prescription drugs
Study: 31223624
Drug: General public
Approvals — FDA: no, EMA: no, PMDA: no
Description: General public awareness of antibiotic use
Study: 31223624
Drug: General public
Approvals — FDA: no, EMA: no, PMDA: no
Description: General public awareness of antibiotic resistance (AR)
Study: 31223624
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of prescription medicine by gender
Study: 31223624
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of antibiotic resistance by occupation
Study: 31223624
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of prescription medicine by ethnicity
Study: 28750585
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg β‐OHB ketone salts
Study: 19151046
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (100-4000 microg)
Study: 11125190
Drug: Tunnel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tunnel preparation
Study: 20188783
Drug: Class II
Normalized name: HLA class II antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class II cavity preparation
Study: 9329638
Drug: Comet assay
Normalized name: Cometriq
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comet assay (single‐cell gel electrophoresis) for measuring DNA strand breaks
Study: 8356846
Drug: Trivalent CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent CR vaccine (A H1N1 (CR‐125), A H3N2 (CR‐149), and B (CRB‐117))
Study: 8356846
Drug: Bivalent CR
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent CR vaccine (CR‐125 and CR‐149)
Study: 8356846
Drug: Inactivated split
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated split vaccine
Study: 3437376
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg orally administered)
Study: 1091686
Drug: Diphenylhydantoin (DPH)
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenylhydantoin (DPH) 100 mg twice daily
Study: 15553010
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (fixed injection rate of 2.0 mL/sec with a 70 sec delay)
Study: 9398090
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic treatment (Control)
Study: 8417877
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg sustained-release, four doses at 12-hour intervals)
Study: 8046314
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg b.i.d.)
Study: 3091717
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (1 g t.i.d.)
Study: 20356395
Drug: Yoga classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga classes (12 weekly sessions)
Study: 31667747
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) sessions (1-on-1)
Study: 29763832
Drug: Regular pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular pain assessment using the Doloplus-2 scale twice a week for 12 weeks
Study: 19213349
Drug: Sanjie Zhentong
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sanjie Zhentong Capsule (SJC)
Study: 16641447
Drug: Cefditoren-pivoxil 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren-pivoxil 200 mg twice daily for 5 days
Study: 16641447
Drug: Cefuroxime-axetil 250
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime-axetil 250 mg twice daily for 10 days
Study: 11959766
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml 0.5% bupivacaine
Study: 2174652
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml 0.9% saline
Study: 9585794
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 to 40 mg/day) + Moclobemide (up to 600 mg/day)
Study: 9585794
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 to 40 mg/day)
Study: 85322
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CHOP + bleomycin or COP + bleomycin)
Study: 30355790
Drug: Subcutaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous treatment with bemiparin 3500 IU/0.2 mL/day
Study: 24702571
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine plus dexmedetomidine administration (Phase M+D)
Study: 24702571
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine administration (Phase M)
Study: 2586565
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical treatment
Study: 17666461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intensive medical treatment and self-management course
Study: 7608322
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration (2 mg)
Study: 7608322
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration (5 mg)
Study: 7608322
Drug: Inhaled administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled administration (2 mg)
Study: 7608322
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Intravenous, Oral, Inhaled)
Study: 323443
Drug: Naloxone, 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 0.01 mg/kg intramuscularly
Study: 17335317
Drug: Topiramate (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (started at 25 mg/day, titrated to 400 mg/day or maximum tolerated dose)
Study: 6762370
Drug: L‐carnitine (1.2‐1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐carnitine (1.2‐1.8 g/day)
Study: 31362119
Drug: Double negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double negative for HBV DNA and RNA at the end of treatment (evaluation cohort)
Study: 31362119
Drug: Positive for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive for either HBV DNA or RNA at the end of treatment (evaluation cohort)
Study: 31362119
Drug: Double negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double negative for HBV DNA and RNA at the end of treatment (validation cohort)
Study: 31362119
Drug: Positive for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive for either HBV DNA or RNA at the end of treatment (validation cohort)
Study: 28342061
Drug: Obinutuzumab in
Normalized name: obinutuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab in combination with chlorambucil (GClb)
Study: 28342061
Drug: Rituximab in
Normalized name: rituximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab in combination with chlorambucil (RClb)
Study: 27423373
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavioural therapy (CBT‐E)
Study: 27423373
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavioural therapy (CBT‐E) and Interpersonal psychotherapy (IPT)
Study: 22818904
Drug: Half-dose verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Half-dose verteporfin photodynamic therapy (PDT)
Study: 15800144
Drug: PROSPECT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PROSPECT intervention (care management model with trained care managers providing algorithm-based recommendations and treatment adherence support over 18 months)
Study: 10559522
Drug: 375 ml
Normalized name: isopropyl alcohol 0.0375 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 ml of red wine (30 g alcohol) per day for 2 weeks
Study: 7505360
Drug: Losartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (20 mg)
Study: 28607125
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg)
Study: 21744761
Drug: Lidocaine 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2.0% (intravenous bolus 1.5 mg/kg followed by an infusion of 1.5 mg/kg/h)
Study: 15953979
Drug: Minimal intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal intervention (verbal information on the Medicaid pharmacotherapy benefit)
Study: 7272163
Drug: Caroxazone 300
Normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroxazone 300 mg/day for 12 days
Study: 7272163
Drug: Caroxazone 600
Normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroxazone 600 mg/day for 12 days
Study: 7272163
Drug: Tranylcypromine 20
Normalized name: tranylcypromine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine 20 mg/day for 8 days
Study: 7272163
Drug: Imipramine 50
Normalized name: trimipramine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 50 mg/day for 12 days
Study: 7272163
Drug: Caroxazone 300
Normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroxazone 300 mg/day
Study: 7272163
Drug: Caroxazone 600
Normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroxazone 600 mg/day
Study: 30391759
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Tranexamic Acid (TXA)
Study: 30391759
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of Tranexamic Acid (TXA)
Study: 28200045
Drug: Single-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimen of Benzathine Penicillin G (2.4 million units)
Study: 28200045
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen of Benzathine Penicillin G
Study: 25389044
Drug: Patent Blue
Normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patent Blue dye injection
Study: 16918888
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg/day)
Study: 11176963
Drug: ABT-431 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-431 (5, 10, 20, and 40 mg)
Study: 7915067
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg/1 min bolus, followed by 0.2 mg/kg/min infusion)
Study: 7915067
Drug: Gallopamil (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (0.025 mg/kg/3 min)
Study: 2968052
Drug: alpha-hANP infusion
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-hANP infusion at 10 pmol.kg‐1.min‐1 for 1 hour
Study: 2968052
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (vehicle)
Study: 2968052
Drug: alpha-hANP infusion
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-hANP infusion
Study: 2968052
Drug: alpha-hANP infusion
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-hANP infusion in normal volunteers
Study: 24074932
Drug: Passively scattered
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passively scattered proton therapy (PSPT)
Study: 24074932
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated photon therapy (IMRT)
Study: 20675936
Drug: Amino-bisphosphonate treatment
Normalized name: (4-amino-1-hydroxybutylidene)bisphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino-bisphosphonate treatment for Osteogenesis Imperfecta
Study: 12667386
Drug: Oseltamivir phosphate,
Normalized name: Oseltamivir Phosphate, 75 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir phosphate, 75 mg twice daily for 5 days
Study: 7408415
Drug: Heparin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (50 U intravenously)
Study: 7408415
Drug: Cumulative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doses of heparin
Study: 7408415
Drug: Heparin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (400 U intravenously of Harris LO14)
Study: 7408415
Drug: Heparin (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (small doses)
Study: 31495331
Drug: Intravenous allogeneic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous allogeneic mesenchymal stem cells (1.5 million cells/kg body weight)
Study: 17729010
Drug: Intravenous anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anticoagulation using i.v. heparin infusion
Study: 15132725
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg/day (low dose group)
Study: 15132725
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg/day (high dose group)
Study: 11463679
Drug: Brief psychodynamic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychodynamic interpersonal therapy
Study: 7739439
Drug: Antibiotic added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic added to sterile physiologic solution
Study: 7739439
Drug: Through drainage
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Through drainage with sterile physiologic solution
Study: 2918157
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.25 mg/kg followed by 0.35 mg/kg body weight)
Study: 163386
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1 gm three times a day for nine months, plus 3 gm daily at onset of cold)
Study: 25936298
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml whipping cream (30% fat)
Study: 25936298
Drug: 0.1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g/kg l‐methionine
Study: 17509903
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide donation via a patch
Study: 15350490
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 24 weeks.
Study: 15350490
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 48 weeks.
Study: 9738086
Drug: Lorazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.1 mg per kilogram)
Study: 9738086
Drug: Phenobarbital (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (15 mg per kilogram)
Study: 9738086
Drug: Diazepam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.15 mg per kilogram) followed by Phenytoin (18 mg per kilogram)
Study: 9738086
Drug: Phenytoin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (18 mg per kilogram)
Study: 9738086
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Lorazepam, Phenobarbital, Diazepam plus Phenytoin, Phenytoin)
Study: 9304981
Drug: Traditional three-day
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional three-day bowel preparation
Study: 4834974
Drug: Carbidopa plus
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa plus 20% of previous levodopa dosage in fixed combination tablets (levodopa:carbidopa in a 10:1 ratio)
Study: 4834974
Drug: Combination tablets
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablets (levodopa:carbidopa in a 10:1 ratio)
Study: 22404184
Drug: Baclofen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (40 mg)
Study: 21654265
Drug: Febuxostat 40
Normalized name: febuxostat 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 40 mg/d
Study: 21654268
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg/d
Study: 25120316
Drug: Febuxostat 120
Normalized name: Febuxostat 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 120 mg/d
Study: 19464611
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 5 L/min
Study: 19464611
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 10 L/min
Study: 16239356
Drug: Ciprofloxacin ER
Normalized name: ciprofloxacin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin ER (500 mg once daily)
Study: 16239356
Drug: Ciprofloxacin IR
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin IR (250 mg twice daily)
Study: 12219247
Drug: Slimming liposomes
Normalized name: arched swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slimming liposomes (SLC) containing esculoside, Centella asiatica extracts, caffeine, and L-carnitine
Study: 8749878
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with low-dose betaxolol (20 mg once daily)
Study: 8749878
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with low-dose diltiazem (90 mg twice daily)
Study: 8749878
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with low-dose diltiazem and digoxin with low-dose betaxolol
Study: 18414916
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg morphine
Study: 1098671
Drug: Teoremac (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teoremac (420 mg/day for 14 days)
Study: 1098671
Drug: Indometacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (100 mg/day for 14 days)
Study: 31366226
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray combined with a newly initiated oral antidepressant
Study: 15800157
Drug: Antidepressant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant plus placebo
Study: 25381345
Drug: Impairment-based approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impairment-based approach focusing on patients' generic abilities and activities of daily living (ADL).
Study: 28640364
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily)
Study: 16936557
Drug: GS-9137 (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9137 (200, 400, or 800 mg BID, 800 mg QD, or 50 mg+100 mg ritonavir QD)
Study: 14505546
Drug: Bifid Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifid Triple Viable capsule (BIFICO), 420 mg/d
Study: 26965429
Drug: Personalized e-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized e-therapy program in addition to usual care
Study: 17981067
Drug: DTPw‐HBV/Hib‐MenAC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw‐HBV/Hib‐MenAC vaccine (2.5 microg of each polysaccharide, 5 microg of each polysaccharide, or 2.5 microg of PRP and 5 microg each of MenA and MenC)
Study: 18478093
Drug: DTPw‐HBV/Hib‐MenAC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw‐HBV/Hib‐MenAC vaccine
Study: 17981067
Drug: Licensed DTPw‐HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed DTPw‐HBV and Hib or DTPw‐HBV/Hib and MenC conjugate vaccines
Study: 10751812
Drug: Pancuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.1 mg kg(‐1))
Study: 10751812
Drug: Pipecuronium (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium (0.07 mg kg(‐1))
Study: 2665352
Drug: ICRC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICRC vaccine
Study: 3965341
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A therapy, 50,000 U twice daily
Study: 24703319
Drug: Non-bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-bevacizumab treatment
Study: 25712298
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg
Study: 17964402
Drug: No ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ocular hypotensive agent (control group)
Study: 16547381
Drug: Indomethacin (INDO)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (INDO) 0.2‐0.2‐0.2 mg/kg